Session Slides

2021

2021 MOPD
New Pediatric Drugs
2021 MOPD
Skin of Color Symposium
2021 SBS
Biologics in Dermatology
2021 SBS
Challenging Cases in Atopic Dermatitis
2021 SBS
Clinical Update: Novel Agents for the Long‐Term Management of Moderate‐to‐Severe Atopic Dermatitis
2021 SBS
Therapeutics on the Horizon
2021 SBS
Current Landscape in the Treatment of Atopic Dermatitis
2021 SBS
Recent Advances in Moderate to Severe AD: JAK Inhibitors
2021 SBS
Tapinarof: Therapeutic AhR Modulating Agent (TAMA)

2020

2020 MOPD
Atopic Dermatitis In Children
2020 MOPD
The Science of Atopic Dermatitis
2020 SBS
Atopic Dermatitis Most Recent Developments and Emerging Therapeutic Options
2020 SBS
Atopic Dermatitis Pathophysiology
2020 SBS
New Applications for Janus Kinase Inhibitors in Dermatology
2020 SBS
Hand Dermatitis

Apr 9, 2021:

Lawrence Schachner,
MD

Atopic Dermatitis Therapy

Lawrence Schachner, MD, discusses recent developments in the pediatric atopic dermatitis treatment landscape, including:

  • Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric AD patients regarding treatment options and at-home interventions?
  • Dupilumab is currently approved for patients with atopic dermatitis aged 6 years and older. Do you foresee dupilumab being approved for even younger patients in the near future?
  • How do emerging JAK inhibitors fit into the existing treatment landscape for pediatric patients with atopic dermatitis?

Podcast also available on:

Apr 9, 2021:

Latanya Benjamin,
MD

Pediatric Skin of Color Symposium: Atopic Dermatitis

Latanya Benjamin, MD, shares clinical pearls about the management of atopic dermatitis in pediatric patients with skin of color, including:

  • Can you tell us about the number of emerging therapies for treatment of AD in pediatric patients and how this will change the treatment landscape?
  • What is your personal approach to treating AD in pediatric patients with skin of color?
  • Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric AD patients regarding treatment options and at-home interventions?

Podcast also available on:

Apr 5, 2021:

Linda Stein Gold,
MD

Clinical Update: Novel Agents for the Long-Term Management of Moderate-to-Severe Atopic Dermatitis

Linda Stein Gold, MD, Chair of the CME Symposium “Clinical Update: Novel Agents for the Long-Term Management of Moderate-to-Severe Atopic Dermatitis” at SBS 2021, leads a panel discussion with Peter Lio, MD and Andrew Alexis, MD, to share clinical pearls and key takeaways about the management of atopic dermatitis.

Podcast also available on:

Jul 27, 2020:

Fernanda Schmidt,
MD

Evolving Paradigms in Atopic Dermatitis

Fernanda Schmidt, MD shares some clinical pearls about the evolving paradigms in AD, including:

  • What are the inside-out and outside-in mechanisms of AD?
  • Is there a difference between these mechanisms across the age spectrum – from children to adults?
  • Can we halt the atopic march by repairing the skin, or is it more than “skin deep”?

Podcast also available on:

Jul 27, 2020:

Leon Kircik,
MD

Perspectives on Emerging AD Therapies

Leon Kircik, MD discusses the potential role of emerging AD treatments, including:

  • Why has atopic dermatitis lagged behind compared to psoriasis in terms of approved targeted treatments?
  • What are some of the most promising therapies that will likely be part of the AD treatment table in the near future?
  • Do you foresee that they will be also approved for pediatric AD, or only for the adult population?
  • In terms of assessing disease severity, how practical are the scales used in clinical trials? Should we put more emphasis on patient-reported outcomes?

Podcast also available on:

Jul 27, 2020:

Lawrence Schachner,
MD

Pearls on Integrating Newer AD Treatments

Lawrence Schachner, MD discusses clinical pearls on the diagnosis and treatment of pediatric AD, including:

  • How do we make sure that we correctly diagnose atopic dermatitis? What are some clinical pearls you can share for our audience?
  • Since now dupilumab is approved for children with atopic dermatitis, what is its role and where would it fit into the “Schachner ladder”?
  • How do crisaborole and dupilumab fit into the long-term care of AD? For how long should they be used?

Podcast also available on:

Jul 27, 2020:

Neal Bhatia,
MD

The Promise of JAK Inhibitors in AD

Neal Bhatia, MD discusses the potential role of JAKis in AD, including:

  • What changes would JAKis bring to the treatment of AD in the near future?
  • What are some JAKis currently under clinical development for AD?
  • Do you foresee that JAKis will play a role in both adult and pediatric AD?
  • Where do you think they will fit in with the other recently-approved treatments for AD, or overall in the treatment regimen?
  • What are the long-term implications for dermatology practice?

Podcast also available on:

Patient Resources

Atopic dermatitis (AD), sometimes called eczema, is one of many allergic skin conditions that affects children and adults. AD is a chronic and often relapsing disease which presents as a dry, scaly rash that be accompanied by redness, itching, oozing, cracking or bleeding. People with AD are more likely to develop another atopic condition and are more prone to infections and mental health conditions. The management of AD involves keeping the skin clean and moisturized, eliminating irritants, using topical and oral medications, and avoiding flares and infections.

Patient Resources

Pediatric Patient Resources